New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ADI;CTRX;DISCA;EQIX;LBTYA;LMCA;REGN;SBAC;VRSK;WDC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 >>
August 31, 2015
07:45 EDTREGNRegeneron should be bought on any pullbacks, says RBC Capital
Subscribe for More Information
06:35 EDTREGNAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTREGNAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
08:01 EDTREGNAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTREGNExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
10:00 EDTWDCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:37 EDTLBTYALiberty Global CEO says no time frame for Vodafone discussions, Reuters says
There was no timeframe for discussions between Liberty Global (LBTYA) and Vodafone (VOD) on swapping assets, Reuters reports, citing Liberty Global's CEO. Reference Link
07:09 EDTWDCWestern Digital initiated with an Outperform at Wells Fargo
Subscribe for More Information
August 25, 2015
08:21 EDTREGNRegeneron has multiple catalysts, says Leerink
Subscribe for More Information
August 24, 2015
08:48 EDTEQIXEquinix management to meet with Gabelli
Subscribe for More Information
07:23 EDTREGNRegeneron should be bought on pullbacks, says RBC Capital
Subscribe for More Information
06:30 EDTDISCADiscovery exec: Group in 'hand to hand combat' with Netflix, Guardian says
Subscribe for More Information
August 23, 2015
12:35 EDTREGNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:40 EDTWDCWestern Digital Q3 TAM tracking ahead of guidance, says Cleveland Research
Subscribe for More Information
August 20, 2015
10:28 EDTADIOptions with decreasing implied volatility
Options with decreasing implied volatility: KING JCP URBN DKS JWN HIG ADI DAR LOW TJX
10:00 EDTADIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:17 EDTDISCADisney hit with another downgrade on TV concerns
Subscribe for More Information
07:35 EDTADIAnalog Devices downgraded to Reduce from Neutral at Nomura
As previously reported, Nomura downgraded Analog Devices (ADI) to Reduce from Neutral. The firm expects consumer revenues to increase to 30% in the October quarter, up from 12% one year ago, driven by Apple (AAPL). The firm believes Apple's contribution isn't worth more than 8-10x earnings or $10 per share, suggesting that at $59, the core business is trading at 22x earnings, suggesting shares are overvalued versus the group that has a multiple of 19x.
06:36 EDTDISCABernstein cuts Disney, Time Warner with TV entering 'structural decline'
Bernstein analyst Todd Juenger downgraded his rating on both Disney (DIS) and Time Warner (TWX) saying the U.S. television industry is entering a period of "prolonged structural decline." With viewers moving away from ad-supported platforms to non-ad-supported, media companies with the least exposure to U.S. advertising represent the most favorable investments, Juenger tells investors in a 48-page research note on the Media sector. The analyst moved both companies to a Market Perform rating from Outperform, and lowered his price target for Disney to $114 from $125 and for Time Warner to $90 from $101. He called the downgrade of Time Warner a "very close call" as his new price target still represents 15% upside from current levels. Share performance in the entire Media sector will be challenged until the content owners take steps to "reclaim on-demand viewing" from streaming services like Netflix (NFLX) and use it to protect affiliate fees, Juenger argues. His Outperform-rated names are Nielsen (NLSN) and 21st Century Fox (FOXA). Along with Time Warner and Disney, the analyst has Market Perform ratings on AMC Networks (AMCX), CBS (CBS), Scripps Networks (SNI) and Discovery (DISCA). Juenger has an Underperform rating on Viacom (VIAB). Wells Fargo on Tuesday also downgraded Disney to Market Perform. Piper Jaffray this morning told investors that the recent pullback in shares of AMC Networks brings a "great" entry point into the name.
06:02 EDTADIAnalog Devices downgraded to Reduce from Neutral at Nomura
Subscribe for More Information
<< 1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use